Three high risk indicators that aid mammography screening

Mammography Reporting System, Inc. (MRS) will demonstrate their newest high risk indicator at RSNA 2009, in Chicago. MRS is the only company in the industry offering three separate high risk indicators to alert radiologists of potentially at-risk patients at the very point they interpret a mammogram.

The importance of relying on more than one high risk model has been outlined by the National Cancer Institute. They say that the Gail model alone significantly underestimates breast cancer risk for women with genetic susceptibility. That's why MRS is leading the way in high risk evaluation. Our reporting system is the only one in the industry that includes three high risk indicators: the results of Gail model calculations, the NCI model calculations, and a model that indicates if a patient is at high risk based on genetic factors.

In MRS, if a patient's demographic history indicates the potential of an inherited risk for breast cancer, it will alert the radiologist that the patient could benefit from increased surveillance or genetic testing. That genetic testing would identify a patient with the BRCA1 or BRCA2 mutation. Those genes are known as tumor suppressors and have been linked to both hereditary breast and ovarian cancer.

MRS's three high risk indicators are changing the landscape in mammography screening. It gives radiologists a better indication when an MRI may be necessary, or other pre-emptive breast care to help patients earlier than ever before.

SOURCE Mammography Reporting System, Inc. (MRS)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lipidomics and metabolomics as potential biomarkers for breast cancer progression